Pelican Therapeutics' Unattributed - II Round

Pelican Therapeutics raised a round of funding on August 18, 2015.

Pelican Therapeutics is developing biologic agents that represent the next generation of TNF based immunotherapy. TNFRSF25 agonists provide a CD8+ T cell and Th1-type antibody adjuvant signal when use…

Articles about Pelican Therapeutics' Unattributed - II Round: